@article{bfa0ef6f51d14471813ed23dd92273fb,
title = "In-hospital pneumococcal polysaccharide vaccination is associated with detection of pneumococcal vaccine serotypes in adults hospitalized for community-acquired pneumonia",
abstract = "During an etiology study of adults hospitalized for pneumonia, in which urine specimens were examined for serotypespecific pneumococcal antigen detection, we observed that some patients received 23-valent pneumococcal polysaccharide vaccine before urine collection. Some urine samples became positive for specific vaccine pneumococcal serotypes shortly after vaccination, suggesting false-positive test results.",
keywords = "Antigen, Pneumococcal conjugate vaccine, Pneumonia, Serotype, Urine",
author = "Grijalva, {Carlos G.} and Wunderink, {Richard G.} and Yuwei Zhu and Williams, {Derek J.} and Robert Balk and Sherene Fakhran and Courtney, {D. Mark} and Anderson, {Evan J.} and Chao Qi and Christopher Trabue and Pavia, {Andrew T.} and Moore, {Matthew R.} and Seema Jain and Edwards, {Kathryn M.} and Self, {Wesley H.}",
note = "Funding Information: Financial support. The EPIC study was supported by Influenza Division in the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention (CDC). C. G. G. was supported in part by the Agency for Healthcare Research and Quality (AHRQ) under Award 1R03HS022342. D. J. W. was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under Award K23AI104779. W. H. S. was supported in part by the National Institute of General Medical Sciences under Award K23GM110469. Funding Information: Potential conflicts of interest. C. G. G. served as consultant for Pfizer Inc. and received research support from the CDC, NIH, AHRQ, the Thrasher Research Fund, and the Bill and Melinda Gates Foundation. R. G. W. served in a Data Safety Monitoring Board for Pfizer Inc. and received research support from Pfizer. D. J. W. received research support from the CDC. R. B. received research support from the CDC. D. M. C. received research support from the CDC and Thermo Scientific BRAHMS. E. J. A. received research support from the CDC, MedImmune, and personal fees from Abbvie and Roche. C. Q. received research support from the CDC. C. T. received support from Saint Thomas Research Institute. A. T. P. received research support from the CDC and personal fees from WebMD, BioFire Dx, and Antimicrobial Therapy Inc. K. M. E. received research support from Novartis. W. H. S. received research support from the CDC, BioMerieux, Affinium Pharmaceuticals, Astute Medical, BRAHMS GmbH/ Thermo Fisher, Pfizer, Rapid Pathogen Screening, Venaxis, BioAegis Inc, Sphingotec GmbH; personal fees from BioFire Diagnostics, Venaxis, Inc; W. H. S. also has a patent 13/632,874 (Sterile Blood Culture Collection System) pending. Funding Information: We thank Pfizer Inc. for conducting the SSUAD assays on the available samples from the Etiology of Pneumonia in the Community (EPIC) study. The EPIC study was supported by Influenza Division in the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention (CDC). C. G. G. was supported in part by the Agency for Healthcare Research and Quality (AHRQ) under Award 1R03HS022342. D. J.W. was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under Award K23AI104779. W. H. S. was supported in part by the National Institute of General Medical Sciences under Award K23GM110469.",
year = "2015",
month = dec,
day = "1",
doi = "10.1093/ofid/ofv135",
language = "English (US)",
volume = "2",
journal = "Open Forum Infectious Diseases",
issn = "2328-8957",
publisher = "Oxford University Press",
number = "4",
}
